[ad_1]
SOUTH SAN FRANCISCO, California, July 18, 2019 – Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading company in the field of allogeneic T-cell immunotherapy developing novel therapeutics for cancer patients, autoimmune diseases Immune and Viral, announced today the price of a public offer of 6,871,727 common shares at a public price of $ 15.28 the action. In addition, Atara Biotherapeutics offers certain investors, in lieu of ordinary shares, warrants pre-financed for the purchase of 2,945,026 common shares at a purchase price of $ 15.2799 per common share. pre-funded, the public offering price per share of the common shares, less the exercise price of $ 0.0001 per share of each of these pre-funded warrants. The total gross proceeds of the Offering are expected to be approximately $ 150.0 million, before deducting discounts and commissions and estimated distribution expenses payable by Atara Biotherapeutics. The closing of the offering is scheduled to occur on or about July 23, 2019, subject to customary closing conditions. As part of the offer, Atara Biotherapeutics has granted the underwriters a 30-day option allowing them to purchase up to 1,472,512 additional shares of their common shares at bid price. to the public, net of discounts and commissions.
Citigroup, Goldman Sachs & Co LLC and Cowen act as joint account managers for the offer. Mizuho Securities and Canaccord Genuity act as co-managers.
The securities described above are offered by Atara Biotherapeutics pursuant to a prior registration statement on Form S-3, including a base prospectus, previously filed by Atara Biotherapeutics with the Securities and Exchange Commission ("SEC"). and became automatically effective February 27, 2018. A preliminary prospectus supplement and the offering prospectus have been filed with the SEC, and a final prospectus supplement and the offering prospectus will be filed with the SEC and will be available. on the SEC website. website located at http://www.sec.gov. Copies of the final Prospectus Supplement and the Prospectus accompanying the Offer, if available, may be obtained from: Citigroup, by mail at the following address: Citigroup Global Markets Inc., c / o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by phone at 1-800-831-9146; Goldman Sachs & Co. LLC, by mail to the address Goldman Sachs & Co. LLC, Attention Prospectus, 200 West Street, New York, NY 10282, by phone at 1-866- 471-2526 or by e-mail at the following address: prospectus-ny @ ny.email.gs.com; or Cowen, by mail to Cowen and Company, LLC, c / o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus, by phone at 1-631-592-5973 or by email to PostSaleManualRequests @ broadridge.com.
This press release does not constitute an offer to sell or the solicitation of an offer to purchase. No sale of such securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the Act. securities laws of such jurisdiction.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a leading company in the field of allogeneic T cell immunotherapy for the development of new therapies for cancer, autoimmune and viral diseases.
Forward-looking statements
This press release contains or may involve "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, forward-looking statements include statements relating to the completion of the public offering. Forward-looking statements are subject to various risks and uncertainties, actual results could differ materially from those projected, and Atara Biotherapeutics cautions investors not to place undue reliance on forward-looking statements in this press release. These risks and uncertainties include, but are not limited to, the risks and uncertainties badociated with market conditions and the satisfaction of customary closing conditions badociated with the public offering. There is no guarantee that Atara Biotherapeutics will be able to supplement the public tender offer under the conditions provided, if at all. The risks and uncertainties badociated with Atara Biotherapeutics and its businesses are set out under the heading "Risk Factors" in Atara Biotherapeutics' Annual Report on Form 10-K filed with the SEC on February 26, 2019 and in subsequent quarterly filings. Form 10-Q. as well as in the preliminary prospectus supplement to the public offering filed with the SEC on July 18, 2019. Unless otherwise provided by law, Atara Biotherapeutics disclaims any intention or obligation to make any or to revise any forward-looking statements only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
INVESTOR CONTACTS AND MEDIA:
investors:
John Craighead, Atara Biotherapeutics
650-410-3012
[email protected]
John Grimaldi, Burns McClellan
212-213-0006 ext. 362
[email protected]
Media:
Robert Flamm, Burns McClellan
212-213-0006 ext. 364
[email protected]
Source link
